Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296864 | 0.83 | CYP2C19 (0.44) | HRH1HTR2A | |
| SCHEMBL3714798 | 0.79 | HSD17B10 (0.48) | HRH1HSD17B10GLATSHRALOX15 | |
| SCHEMBL1975183 | 0.79 | USP2 (0.37) | — | |
| SCHEMBL8293251 | 0.78 | POLB (0.40) | ALDH1A1POLB | |
| SCHEMBL1975184 | 0.76 | — | — | |
| SCHEMBL1970098 | 0.74 | PLG (0.35) | HSD17B10ALDH1A1LMNANPSR1KDM4E | |
| SCHEMBL1969361 | 0.73 | DPP4 (0.35) | HSD17B10ALDH1A1NPSR1 | |
| SCHEMBL5327581 | 0.72 | HRH1 (0.44) | HRH1HTR2ANPSR1 | |
| SCHEMBL16075569 | 0.69 | KDM4E (0.41) | HSD17B10GLATSHRALOX15ALDH1A1 | |
| SCHEMBL6226343 | 0.69 | CYP2C19 (0.40) | HRH1HTR2AMAPK1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1758891-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | Pfizer Japan Inc. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2005123718-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | PFIZER JAPAN INC. (JP) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | HRH1 18/4885HSD17B10 2222/4885HTR2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.